Astex in the News
2O24
Astex wins the Research and Development Achievement Award at the Pharma Awards
Sept 2024, Pharma Industry Awards UK website – read more
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Sept 2024, Novartis website – read more
OpenFold AI Research Consortium Welcomes Six New Members: Astex, Biogen, Congruence, Polaris Quantum, Psivant, and SandboxAQ
August 2024, Business Wire press release – read more
AI and Drug Discovery with Harren Jhoti
July 2024, Bloomberg podcast – listen
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
July 2024, Labiotech – read more
MHRA approves first-in-class breast cancer drug
July 2024, ICR website – read more
Jessie Stow, Astex Pharmaceuticals apprentice, wins prestigious Royal Society of Chemistry Prize
June 2024, RSC website – read more
Harren Jhoti discusses Astex’s discovery and preclinical work that has contributed to three approved medicines
May 2024 – watch video
Cambridge A-listers Astex and AstraZeneca toast progress of another cancer drug prospect
January, Business Weekly (page 23) – read more
2O23
Interview with Harren Jhoti: How Astex built a business based on fragment-based drug discovery
Nov – Dec, MedNous – Issue 2023 – read more
Third Success from Astex Drug Discovery Pharma Collaborations as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib).
November 17, 2023 – read more
Dr Harren Jhoti FRS OBE wins Business Person of the Year at the 21st annual Asian Achievers Awards
September 15, 2023 – read more
Astex bags another cancer deal with MSD, this time for “undruggable” p53 target
August 9, 2023 – read more
UK’s Astex adds onto Merck partnership via $35M upfront for tumor suppressor protein candidates
August 8, 2023 – read more
Merck enlists Astex to search for p53 cancer drug in expanded deal
August 8, 2023 – read more
Astex hails trials success of superdrug that saves lives and cuts recurrence risk for thousands of breast cancer patients
June 7, 2023 – read more
Breast cancer drug cuts risk of most common form returning by 25%
June 2, 2023 – read more
Astex wins Life Science Company of the Year at the Cambridge Independent Science and Technology Awards 2023
May 18, 2023 – read more
Astex is a finalist for the Cambridge Independent Science and Technology Awards 2023
March 15, 2023 – read more
Astex and Cardiff University Medicines Discovery Institute to Collaborate on neurodegenerative diseases
February 14, 2023 – read more
Cardiff University and Astex in drug discovery collaboration
February 13, 2023 – read more
Astex and Cardiff University seek new drugs to treat neurodegenerative diseases
February 13, 2023 – read more
Fit for a king! Astex chief made OBE in historic honours list
January 3, 2023 – read more
Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours
January 1, 2023 – read more
2O22
Astex and AstraZeneca deliver ‘landmark’ breast cancer drug
December 15, 2022 – read more
Cambridge on the cusp of its third blockbuster drug coup
December 13, 2022 – read more
New targeted drug shows benefit against breast cancer in first phase III trial
December 9, 2022 – read more
New targeted drug shows benefit against breast cancer in first phase III trial
December 8, 2022 – read more
Cryo-EM Incites a “Resolution Revolution,” Rousing Drug Discovery article – Includes interview with Astex’s Senior Director (Molecular Sciences) Dr. Pamela Williams featured in the Cryo-EM meets fragment-based drug design section
December 7, 2022 – read more
Cancer Research UK and Newcastle University announce alliance extension with Astex Pharmaceuticals (UK)
November 22, 2022 – read more
Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
October 26, 2022 – read more
Astex wins 3 awards for participating in The BioIndustry Association (BIA) 850 Global Challenge for Kidney Research UK 2022
May 30, 2022 – read more
Astex enters new partnership with the UK Dementia Research Institute to accelerate progress in dementia research
April 6, 2022 – read more
2O21
David Rees, Chief Scientific Officer, joins The Rosalind Franklin Institute (RFI) Board of Directors
September 1, 2021 – read more
Astex scientist, Pamela Williams, wins the Biochemical Society’s Industry and Academic Collaboration Award
September, 2021 – read more
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program
January 13, 2021 – read more
2O2O
David Rees, Chief Scientific Officer, inducted to the Royal Society of Chemistry BMCS (Biological and Medicinal Chemistry Sector) Hall of Fame
December 1, 2020 – read more
Astex’s VP Intellectual Property, Michelle Jones, is named as one of the Managing IP Corporate IP Stars of 2020
July 28, 2020 – read more
Astex CSO, David Rees, elected as new Fellow of the Academy of Medical Sciences
May 13, 2020 – read more
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex (KRAS programme)
January 6, 2020 – read more
2O19
An Entrepreneurs Journey Part II: Harren Jhoti, President and CEO Astex Pharmaceuticals
Nov 25, 2019 – Read more
An Entrepreneurs Journey Part I: Harren Jhoti, President and CEO Astex Pharmaceuticals text
Nov 22, 2019 – Read more
Astex is featured in Biology Impacting Lives, an ITN Productions programme created in partnership with the Royal Society of Biology
April 15, 2019 – view video
https://astx.com/wp-admin/post.php?post=1618&action=edit&classic-editor=1#save
2O15
Open Innovation: The Answer To Slow Pharmaceutical Productivity
September 1, 2015 – read more
© Astex Pharmaceuticals
All rights reserved
